Drug Trial Radar · NCT00772382
Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
Dec 2008
Primary completion
Aug 2010
Study completion Aug 2010
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Oct 15, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to demonstrate the long-term safety and tolerability of MCI-196 in the subjects with stage V chronic kidney disease on dialysis with hyperphosphatemia. The secondary objective of this study is to assess the long-term efficacy of flexible doses of MCI-196.
Conditions
- Chronic Kidney Disease
- Dialysis
- Hyperphosphatemia
Interventions
MCI-196Drug
3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse Events (AE)Time frame: 52 weeks
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
Orange, California
Site not named
Tarzana, California
Site not named
Orlando, Florida
Site not named
Pembroke Pines, Florida
Site not named
Atlanta, Georgia
Site not named
Gurnee, Illinois
Site not named
Evansville, Indiana
Site not named
Baton Rouge, Louisiana
Site not named
New Orleans, Louisiana
Site not named
Northport, New York
Site not named
Durham, North Carolina
Site not named
Oklahoma City, Oklahoma
Site not named
Nashville, Tennessee
Site not named
Houston, Texas
Site not named
Burlington, Vermont
Site not named
Chesapeake, Virginia
Site not named
Kamloops, British Columbia, Canada
Site not named
London, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.